PROCESSA PHARMACEUTICALS PROVIDES AN UPDATE ON POSITIVE RESULTS FROM PCS-499 PHASE 2 TRIAL
04 déc. 2019 09h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
CureVac erhält Herstellungserlaubnis für dritte GMP-Produktion
02 déc. 2019 07h00 HE
|
CureVac AG
Alle drei GMP-Produktionen von CureVac können damit Wirkstoffe für präklinische und klinische Tests sowie für die frühe Markteinführung herstellen TÜBINGEN, Deutschland und BOSTON, Dec. 02,...
CureVac Granted Manufacturing Authorization for its Third GMP Production Suite
02 déc. 2019 07h00 HE
|
CureVac AG
CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs TÜBINGEN, Germany and...
CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference
20 nov. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief...
Trevi Therapeutics to Present at Stifel Healthcare Conference
13 nov. 2019 17h01 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
06 nov. 2019 05h30 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Cytovance® Biologics Introduces an Integrated Single-use Platform for Plasmid DNA (pDNA) Manufacture
21 oct. 2019 12h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Cytovance Biologics is a leading biopharmaceutical CDMO with a 15-year track record of supplying drug substance to clients, offering fast and...
Cytovance Biologics to Participate in RAFT Scientific Discussion on Commercialization of Fermentation Processes
18 oct. 2019 17h24 HE
|
Cytovance Biologics
OKLAHOMA CITY, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate...
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO
18 oct. 2019 06h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month
16 oct. 2019 08h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...